Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation
View ORCID ProfileMarika Watanabe, View ORCID ProfileKimikazu Yakushijin, View ORCID ProfileYohei Funakoshi, View ORCID ProfileGoh Ohji, Hironori Sakai, Wataru Hojo, Miki Saeki, Yuri Hirakawa, Sakuya Matsumoto, Rina Sakai, Shigeki Nagao, Akihito Kitao, Yoshiharu Miyata, Taiji Koyama, Yasuyuki Saito, Shinichiro Kawamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
doi: https://doi.org/10.1101/2021.12.28.21268477
Marika Watanabe
1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
Kimikazu Yakushijin
1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
Yohei Funakoshi
1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
Goh Ohji
2Division of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan
Hironori Sakai
3R&D, Cellspect Co., Ltd., Morioka, Iwate, Japan
Wataru Hojo
3R&D, Cellspect Co., Ltd., Morioka, Iwate, Japan
Miki Saeki
1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
Yuri Hirakawa
1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
Sakuya Matsumoto
1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
Rina Sakai
1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
Shigeki Nagao
1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
Akihito Kitao
1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
Yoshiharu Miyata
4BioResource Center, Kobe University Hospital, Kobe, Japan
Taiji Koyama
1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
Yasuyuki Saito
5Division of Molecular and Cellular Signaling, Kobe University Graduate School of Medicine, Kobe, Japan
Shinichiro Kawamoto
1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
Mitsuhiro Ito
1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
6Laboratory of Hematology, Division of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
Tohru Murayama
1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
7Hematology Division, Hyogo Cancer Center, Akashi, Japan
Hiroshi Matsuoka
4BioResource Center, Kobe University Hospital, Kobe, Japan
Hironobu Minami
1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
8Cancer Center, Kobe University Hospital, Kobe, Japan
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Posted December 29, 2021.
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation
Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, Goh Ohji, Hironori Sakai, Wataru Hojo, Miki Saeki, Yuri Hirakawa, Sakuya Matsumoto, Rina Sakai, Shigeki Nagao, Akihito Kitao, Yoshiharu Miyata, Taiji Koyama, Yasuyuki Saito, Shinichiro Kawamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
medRxiv 2021.12.28.21268477; doi: https://doi.org/10.1101/2021.12.28.21268477
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation
Marika Watanabe, Kimikazu Yakushijin, Yohei Funakoshi, Goh Ohji, Hironori Sakai, Wataru Hojo, Miki Saeki, Yuri Hirakawa, Sakuya Matsumoto, Rina Sakai, Shigeki Nagao, Akihito Kitao, Yoshiharu Miyata, Taiji Koyama, Yasuyuki Saito, Shinichiro Kawamoto, Mitsuhiro Ito, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
medRxiv 2021.12.28.21268477; doi: https://doi.org/10.1101/2021.12.28.21268477
Subject Area
Subject Areas
- Addiction Medicine (357)
- Allergy and Immunology (681)
- Anesthesia (182)
- Cardiovascular Medicine (2694)
- Dermatology (229)
- Emergency Medicine (405)
- Epidemiology (12334)
- Forensic Medicine (10)
- Gastroenterology (773)
- Genetic and Genomic Medicine (4171)
- Geriatric Medicine (393)
- Health Economics (689)
- Health Informatics (2703)
- Health Policy (1010)
- Hematology (366)
- HIV/AIDS (864)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (446)
- Neurology (3954)
- Nursing (214)
- Nutrition (587)
- Oncology (2084)
- Ophthalmology (596)
- Orthopedics (245)
- Otolaryngology (308)
- Pain Medicine (254)
- Palliative Medicine (75)
- Pathology (474)
- Pediatrics (1134)
- Primary Care Research (462)
- Public and Global Health (6593)
- Radiology and Imaging (1431)
- Respiratory Medicine (879)
- Rheumatology (416)
- Sports Medicine (345)
- Surgery (456)
- Toxicology (56)
- Transplantation (191)
- Urology (170)